What is the prevalence of Chronic myelogenous leukemia (CML)?

Chronic myelogenous leukemia (CML) is a myeloproliferative neoplasm with an estimated prevalence of approximately 1 to 2 cases per 100,000 people globally. While considered a rare disease, the prevalence is steadily increasing due to the efficacy of targeted therapies that significantly extend survival for those living with Chronic myelogenous leukemia (CML).

What is the incidence and prevalence of Chronic myelogenous leukemia (CML)?

The annual incidence of Chronic myelogenous leukemia (CML) is estimated at 0.6 to 2.0 per 100,000 individuals. Because patients are now living much longer due to tyrosine kinase inhibitors (TKIs), the overall prevalence of Chronic myelogenous leukemia (CML) continues to rise, shifting it from a fatal diagnosis to a manageable chronic condition. It is important to note that these figures are estimates; true prevalence may be higher in regions with limited access to diagnostic bone marrow testing or molecular genetic screening.

Who is most affected by Chronic myelogenous leukemia (CML)?

Chronic myelogenous leukemia (CML) shows a slight male predilection, with a male-to-female ratio of approximately 1.3:1. While the disease can occur at any age, the median age at diagnosis is typically between 60 and 65 years. Pediatric cases are rare, accounting for less than 5% of all Chronic myelogenous leukemia (CML) diagnoses. There is no significant evidence of geographic or ethnic variation in the incidence of this condition, as it is primarily driven by the somatic acquisition of the BCR-ABL1 fusion gene.

What are the challenges in tracking Chronic myelogenous leukemia (CML) data?

Accurate epidemiological tracking is complicated by several factors:

• Underdiagnosis: Some patients in the early chronic phase are asymptomatic and may not seek medical attention until the disease progresses.


• Diagnostic variance: Access to the specialized cytogenetic testing required to confirm Chronic myelogenous leukemia (CML) varies globally.


• Real-world data: Our DiseaseMaps.org community currently hosts 287 people with Chronic myelogenous leukemia (CML), providing a vital, patient-centered perspective on the lived experience that complements formal clinical registry data.

Next steps

• Consult a hematologist or oncologist for standardized molecular monitoring.


• Join the DiseaseMaps.org community to connect with others sharing their experiences.


• Inquire about clinical trials for new-generation TKI therapies if you are treatment-resistant.

Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Chronic Myelogenous Leukemia.


• Orphanet: Chronic Myeloid Leukemia (ORPHA:523).


• National Cancer Institute (NCI): Chronic Myelogenous Leukemia Treatment (PDQ®).


• OMIM (Online Mendelian Inheritance in Man): Leukemia, Chronic Myeloid (Entry #608232).